Stay updated on Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial

Sign up to get notified when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for a Phase 2 study of daratumumab plus ibrutinib for Waldenström macroglobulinemia, with study methods, eligibility, and outcome measures. It indicates the study was terminated for low accrual and is no longer seeking participants.
    Difference
    56%
    Check dated 2026-11-09T13:17:22.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label changed from `v3.7.2` to `v3.8.0`.
    Difference
    0.2%
    Check dated 2026-11-02T12:58:08.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A banner was added announcing changes to NIH terminology and linking to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T13:25:12.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2, while the study record page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T13:43:43.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-12T14:20:29.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page, replacing the usual study content and navigation. This indicates restricted access to the study record and a disrupted user experience on this page.
    Difference
    20%
    Check dated 2026-09-21T22:13:14.000Z thumbnail image

Stay in the know with updates to Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab Plus Ibrutinib in Waldenstrӧm's Clinical Trial page.